OOOkan Orhan

Okan Orhan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Okan Orhan has a total of 88 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Effect of radiotherapy on psychiatric disorder in patients with head and neck cancer

    by D Unal, O Orhan, Sd Ozsoy, A Besirli, C Eroglu, B Kaplan

    Purpose: The aim of this prospective study was to evaluate the effects of radiotherapy (RT) on psychiatric disorder in patients undergoing RT for head and neck cancer. Materials and Methods: The prospective study included 51 patients with head and neck cancer. The diagnosis of psychiatric disorder was made by Diagnostic and Statistical Manual of Mental Disorders, 4th edition criteria. Severity of psychopathology was assessed by the Hamilton Depression Rating Scale (HAM-D). Results: Although HAM-D score increased after RT (from 4 [0-26] to 7 [0-24]), this increase was not significant (P = 0.108). Fourteen (27.5%) of 51 patients had a psychiatric disorder before RT treatment; adjustment disorder in 6, depression in 4, sleep disorder in 3, anxiety disorder in 1 patient. On the other hand, 16 (31.4%) of 51 patients had a psychiatric disorder after RT treatment; adjustment disorder in 6, depression in 5, sleep disorder in 4, anxiety disorder in 1 patient. There was no significant difference between two periods in terms of the prevalence of psychiatric disorder (P = 0.721). Conclusions: The presence of psychiatric disorder was high in patients with head and neck cancer even before RT. Similarly, its high rate continued after RT. However, there is no significant effect of RT on development of psychiatric disorder.


    • 28 July 2015
      • Vol. 20  (3) , 886-93

    Effect on long-term survival of psychiatric disorder, inflammation, malnutrition, and radiotherapy-related toxicity in patients with locally advanced head and neck cancer.

    by Dilek Unal, Celalettin Eroglu, Saliha Demirel Ozsoy, Asli Besirli, Okan Orhan, Bunyamin Kaplan

    To evaluate the effects on the long-term survival of psychiatric disorders, inflammation, malnutrition, and radiotherapy (RT)-related toxicity in patients with locally advanced head and neck cancer. Included were 47 patients who received RT for non-metastatic locally advanced head and neck cancer. The diagnosis of psychiatric disorder was made by the Diagnostic and Statistical Manual of Mental disorders (4th edn) (DSM-IV) criteria. Malnutrition was defined as weight loss >5% of baseline during RT. Interleukin 1β (IL-1β), IL-6, and tumor necrosis factor-alpha (TNF-α) were analyzed by enzyme-linked immunosorbent assay (ELISA). RT-related acute toxicity was evaluated once a week using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 2.0. The mean patient age was 57.3±11.4 years (range 33-80); 42 (89.4%) patients were male. Mean disease-free (DFS) and overall survival (OS) were 53 and 55 months, respectively. Mean DFS was significantly lower in patients with psychiatric disorder compared with those without (35 vs 59 months, p=0.013) and the same applied for mean OS (41 vs 61 months, p=0.008). There was no significant difference between patients with and without malnutrition in terms of OS. Similarly, no significant difference was seen between patients with and without RT-related toxicities in terms of OS. Age, psychiatric disorder, T status, and stage differed significantly between these groups (p<0.10) in univariate analysis. The multivariate Cox regression analysis identified that the OS was significantly associated only with psychiatric disorder (odds ratio/OR: 3.22, 95% confidence interval/CI: 1.29-8.41, p=0.013). Psychiatric disorders had unfavorable effects on OS in patients with locally advanced head and neck cancer. Inflammation, malnutrition and RT-related toxicity had no significant impact on OS.


  • Contribution of Involved-field Radiotherapy to Survival in Patients With Relapsed or Refractory Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

    by Celalettin Eroglu, Leylagül Kaynar, Okan Orhan, Muzaffer Keklik, Cem Sahin, Oğuz G. Yildiz, Selahattin Mentes, Fatih Kurnaz, Dicle Aslan, Serdar Sivgin, et al.

    To assess the outcomes of overall survival and posttransplantation survival in patients with Hodgkin lymphoma (HL) undergoing autologous stem cell transplantation (ASCT) because of the development of relapse or resistance after chemotherapy (CT) or CT plus radiotherapy (combined modality treatment, CMT). Forty-five patients undergoing ASCT because of the development of relapse or resistance after CT or CMT for HL were enrolled in the study. Radiotherapy was given as involved-field radiotherapy. Patients were treated with CT alone (n=25) or CMT (n=20). These 2 groups were further divided into 2 subgroups: the patients with early-stage (I to II) and advanced-stage (III to IV) HL. Median patients age was 29 years (range, 16 to 60 y) and the median follow-up was 60 months (range, 12 to 172 mo). In the patients with advanced-stage HL, there was no statistically significant difference in overall survival between irradiated and nonirradiated patients (n=18, irradiated n=4 and nonirradiated n=14). However, in the patients with early-stage disease, there was a significant difference in 5- and 10-year overall survival between the irradiated and nonirradiated groups (81% vs. 48% and 66% vs. 24%, respectively, P=0.045; n=26, irradiated n=16 and nonirradiated n=10). In the univariate analysis, irradiated group and involvement of 1 to 2 nodal regions were found to be significant for overall survival, whereas irradiated group, early stage, and involvement of 1 to 2 nodal regions were found to be significant for posttransplantation survival. However, only irradiated group was found to be significant for posttransplantation survival in multivariate analysis (P<0.05). Addition of involved-field radiotherapy to CT in patients undergoing ASCT after relapse or recurrence failed to provide survival benefit in patients with advanced HL, while a survival benefit was observed in patients with early-stage HL. Radiotherapy should be considered as part of CMT in the patients with early-stage HL, which should not be neglected.


  • Open Access

    Prognostic Value of SPARC Expression in Unresectable NSCLC Treated with Concurrent Chemoradiotherapy

    by Neslihan Kurtul, Celalettin Eroglu, Dilek Unal, Erdem Arzu Tasdemir, Okan Orhan, Gokmen Zararsiz, Munevver Baran, Bunyamin Kaplan, Olgun Kontas

    Prognostic Value of SPARC Expression in Unresectable NSCLC Treated with Concurrent Chemoradiotherapy NSCLC;SPARC expression;prognosis;chemoradiotherapy; Background: The aim of the present study was to determine the predictive/prognostic value of the secreted protein, acidic and rich in cysteine (SPARC) in cases of unresectable, locally advanced, non-small cell lung cancer. Materials and Methods: The study included 84 patients with Stage IIIA-B non-small cell lung cancer, undergoing simultaneous chemoradiotherapy including radiotherapy at a dose of 66 Gy and weekly docataxel ($20mg/m^2$) and cisplatin ($20mg/m^2$). SPARC expression was studied in biopsy material by immunohistochemical methods and correlations with treatment responses or survival were evaluated. Results: Median overall survival was $16{\pm}2.73$ (11.55-20.46) months for low expression vs $7{\pm}1.79$ months (7.92-16.08) months for high expression (p=0.039), while median local control was $13{\pm}2.31$ (8.48-17.5) months for low expression vs $6{\pm}0.85$ (4.34-7.66) months for high expression (p=0.045) and median progression-free survival was $10{\pm}2.31$ (5.48-14.5) months for low expression vs $6{\pm}1.10$ (3.85-8.15) months for high expression (p=0.022). In both univariate and multivariate analyses, high SPARC expression was associated with significantly shorter overall survival (p=0.003, p=0.007, respectively), local control (p=0.008, p=0.036) and progression-free survival (p=0.004, p=0.029) when compared to low SPARC expression. No significant difference was detected between high and low SPARC expression groups regarding age, sex, T stage, N stage, histopathology and stage-related patient characteristics. Conclusions: High SPARC expression was identified as a poor prognostic factor in cases with locally advanced NSCLC treated with concurrent chemoradiotherapy.


  • Comparison of total body irradiation plus cyclophosphamide with busulfan plus cyclophosphamide as conditioning regimens in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplant

    by Celalettin Eroglu, Cigdem Pala, Leylagül Kaynar, Kadir Yaray, M. Tarkan Aksozen, Mehmet Bankir, Gökmen Zararsız, Okan Orhan, Mete Gündog, Oguz G. Yıldız, et al.

    Conditioning regimens used during stem cell transplant provide prolonged control or cure of the disease in patients with acute lymphoblastic leukemia (ALL). In this study, we present a comparison of treatment results for 95 patients with ALL who underwent allogeneic hematopoietic stem cell transplant (AHSCT) with total body irradiation plus cyclophosphamide (TBI + Cy) or busulfan plus cyclophosphamide (Bu + Cy) as conditioning regimen. Median age was 25 (range: 9–54) years. Median follow-up was 24 (range: 3–107) months. Median overall survival (OS) was found to be 29 months. Median event-free survival (EFS) was 9 months. Median OS was 37 months in the TBI + Cy arm, while it was 12 months in the Bu + Cy arm, suggesting a significant advantage favoring the TBI + Cy arm (p = 0.003). Median EFS was 13 months in the TBI + Cy arm, while it was 4 months in the Bu + Cy arm, indicating a significant difference (p = 0.006). In univariate and multivariate analysis, it was found that high OS and EFS were significantly correlated with TBI + Cy conditioning regimen and lack of transplant-related mortality (p < 0.05). The TBI + Cy conditioning regimen was found to be superior to the Bu + Cy regimen in patients with ALL undergoing AHSCT regarding both OS and EFS.


  • Open Access

    Prealbumin is a more sensitive marker than albumin to assess the nutritional status in patients undergoing radiotherapy for head and neck cancer

    by Dilek Unal, Okan Orhan, Celalettin Eroglu, Bunyamin Kaplan

    Aim of the study : The aim of this prospective study was to determine the prevalence of malnutrition and to evaluate a more sensitive marker to assess the nutritional status in patients undergoing RT for head and neck cancer. Material and methods : The prospective study included 51 (mean age...


  • Open Access

    Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer

    by Celalettin Eroglu, Okan Orhan, Dilek Unal, Gamze G Dogu, Halit Karaca, Mustafa Dikilitas, Ahmet Oztürk, Metin Ozkan, Bünyamin Kaplan

    Objectives: To evaluate treatment results and toxicities in patients who received concomitant chemoradiotherapy (CRT) followed by consolidation with docetaxel and cisplatin in locally advanced unresectable non-small cell lung cancer (NSCLC). Methods: Ninety three patients were included in this retrospective study. The patients received 66 Gy radiotherapy and weekly 20 mg/m 2 docetaxel and 20 mg/m 2 cisplatin chemotherapy concomitantly. One month later than the end of CRT, consolidation chemotherapy with four cycles of docetaxel 75 mg/m 2 and cisplatin 75 mg/m 2 were administered at each 21 days. Results: Median age of the patients was 57 (range, 30-74). Following concomitant CRT, 14 patients (15%) showed complete and 50 patients (54%) showed partial response (total response rate was 69%). The median follow-up was 13 months (range: 2-51 months). The median overall survival was 18 months (95% confidential interval [CI]: 13.8-22.1 months); local control was 15 months (95% CI: 9.3-20.6 months); progression-free survival was 9 months (95% CI: 6.5-11.4 months). Esophagitis in eight (9%) patients, neutropenia in seven (8%) patients and pneumonitis in eight (9%) patients developed as grade III-IV toxicity due to concomitant CRT. Conclusion: Concomitant CRT with docetaxel and cisplatin followed by docetaxel and cisplatin consolidation chemotherapy might be considered as a feasible, and well tolerated treatment modality with high response rates despite the fact that it has not a survival advantage in patients with locally advanced unresectable NSCLC.


  • The effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy

    by C. Eroglu, O. Orhan, H. Karaca, D. Unal, M. Dikilitas, M. Ozkan, B. Kaplan

    EROGLU C., ORHAN O., KARACA H., UNAL D., DIKILITAS M., OZKAN M. & KAPLAN B. (2013) European Journal of Cancer Care22, 133–140 The effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy The aim of this study was to examine the effect of being overweight on survival in patients with gastric cancer undergoing adjuvant chemoradiotherapy and chemotherapy. In this study 152 patients were evaluated. Radiotherapy dose was 45 Gy given in 5 weeks. 5‐FU 425 mg/m2 and folinic acid 20 mg/m2 were administered weekly during the radiotherapy and four cycles with 4‐week intervals as consolidation chemotherapy after radiotherapy. Patients were assigned into two groups according to their body mass index: overweight (body mass index ≥25 kg/m2) and normal weight (body mass index 2). The median overall survival was 39 months vs. 18 months and median disease‐free survival was 27 months vs. 13 months in the overweight and normal‐weight groups respectively (P= 0.004 and P= 0.006 respectively). The 5‐year survival was better in the patients with overweight than those with normal weight (42% vs. 17%; P= 0.004). The overall survival was significantly better with being overweight and early pathological stage (P= 0.016 and P= 0001 respectively). Overall survival, disease‐free survival and long‐term survival in patients with gastric cancer undergoing adjuvant treatment were better in overweight than normal‐weight patients. Moreover, it was shown that body mass index and pathological stage were associated to survival and prognosis.


    • 1 August 2012
      • Vol. 32  (8) , 3587-90

    Effect of serum selenium levels on radiotherapy-related toxicity in patients undergoing radiotherapy for head and neck cancer.

    by Celalettin Eroglu, Dilek Unal, Aysun Cetin, Okan Orhan, Serdar Sivgin, Ahmet Oztürk

    To investigate whether there is a difference in selenium levels before and after radiotherapy (RT) and to study the effects of serum selenium levels on RT-related toxicity in patients undergoing RT for head and neck cancer. A population of 47 consecutive patients was enrolled in the study. RT was given by conventional fractionation. RT-related acute toxicity was evaluated once a week. Blood samples were obtained before and after RT to evaluate selenium levels. There was no significant difference between the levels of selenium before and after RT (58.09 ± 1.36 μg/l and 56.34 ± 1.11 μg/l, p-value=0.747, respectively). Grade III-IV mucositis, dysphagia, radiodermatitis, and nausea were seen in 6 (12.7%), 32 (68.2%), 24 (51.1%), and 3 (6.4%) patients, respectively. It was found that there was no statistically significant difference in the levels of selenium before and after RT, and no observed differences in regard to RT-related toxicities. The serum selenium levels do not affect RT-related toxicities.